X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES IPCA LABS VENUS REMEDIES/
IPCA LABS
 
P/E (TTM) x -3.4 29.1 - View Chart
P/BV x 0.1 3.7 3.4% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 VENUS REMEDIES   IPCA LABS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
IPCA LABS
Mar-18
VENUS REMEDIES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs126695 18.1%   
Low Rs61400 15.3%   
Sales per share (Unadj.) Rs301.8260.2 116.0%  
Earnings per share (Unadj.) Rs-24.919.0 -131.1%  
Cash flow per share (Unadj.) Rs2.533.1 7.7%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs293.3213.0 137.7%  
Shares outstanding (eoy) m12.34126.20 9.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.1 14.7%   
Avg P/E ratio x-3.828.9 -13.0%  
P/CF ratio (eoy) x36.716.6 221.8%  
Price / Book Value ratio x0.32.6 12.4%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m1,15469,120 1.7%   
No. of employees `0000.913.3 7.0%   
Total wages/salary Rs m3937,359 5.3%   
Avg. sales/employee Rs Th4,026.12,477.4 162.5%   
Avg. wages/employee Rs Th425.0555.2 76.5%   
Avg. net profit/employee Rs Th-331.8180.6 -183.7%   
INCOME DATA
Net Sales Rs m3,72432,836 11.3%  
Other income Rs m23418 5.4%   
Total revenues Rs m3,74733,254 11.3%   
Gross profit Rs m3954,505 8.8%  
Depreciation Rs m3381,777 19.0%   
Interest Rs m354240 147.5%   
Profit before tax Rs m-2752,905 -9.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32511 6.2%   
Profit after tax Rs m-3072,394 -12.8%  
Gross profit margin %10.613.7 77.3%  
Effective tax rate %-11.517.6 -65.2%   
Net profit margin %-8.27.3 -113.0%  
BALANCE SHEET DATA
Current assets Rs m2,63819,455 13.6%   
Current liabilities Rs m2,30510,076 22.9%   
Net working cap to sales %8.928.6 31.3%  
Current ratio x1.11.9 59.3%  
Inventory Days Days13598 138.3%  
Debtors Days Days4667 69.2%  
Net fixed assets Rs m4,87120,260 24.0%   
Share capital Rs m123252 48.9%   
"Free" reserves Rs m3,49626,633 13.1%   
Net worth Rs m3,61926,886 13.5%   
Long term debt Rs m1,3742,340 58.7%   
Total assets Rs m7,50941,173 18.2%  
Interest coverage x0.213.1 1.7%   
Debt to equity ratio x0.40.1 436.3%  
Sales to assets ratio x0.50.8 62.2%   
Return on assets %0.66.4 9.9%  
Return on equity %-8.58.9 -95.2%  
Return on capital %1.610.8 14.7%  
Exports to sales %047.6 0.0%   
Imports to sales %13.914.9 93.3%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs m5174,884 10.6%   
Fx inflow Rs m015,642 0.0%   
Fx outflow Rs m5174,884 10.6%   
Net fx Rs m-51710,759 -4.8%   
CASH FLOW
From Operations Rs m5143,411 15.1%  
From Investments Rs m-123-1,354 9.1%  
From Financial Activity Rs m-387-1,304 29.7%  
Net Cashflow Rs m4753 0.6%  

Share Holding

Indian Promoters % 32.9 45.9 71.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.4 1.6%  
FIIs % 0.6 25.3 2.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.4 381.6%  
Shareholders   20,121 36,892 54.5%  
Pledged promoter(s) holding % 36.4 2.1 1,699.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   MERCK LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Recover; Healthcare & IT Stocks Witness Buying(12:30 pm)

Share markets in India have trimmed their early losses and are presently trading marginally lower. Sectoral indices are trading mixed with stocks.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Dec 11, 2018 01:15 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS